ABSTRACT
Se presenta un caso clínico de linfoma primario de la mama, patología de muy baja ocurrencia (0.1 por ciento de los cánceres de mama), en una mujer de 71 años, diagnosticado y tratado en la Unidad de Patología Mamaria del Servicio de Obstetricia y Ginecología del Hospital San Borja Arriarán en enero del 2002
Subject(s)
Humans , Female , Aged , Breast Neoplasms , Lymphoma , Biopsy , Breast Neoplasms , Lymphoma , Mastectomy, Simple , PrognosisABSTRACT
La radioquimioterapia ha sido descrita como una alternativa frente a la cirugía radical, en pacientes portadores de un cáncer vesical localmente avanzado, y que no pueden ser sometidos a ella por algún tipo de contraindicación. Se analizan en forma retrospectiva 24 pacientes con un cáncer vesical avanzado (T2 y T3), sometidos a una RTUV profunda más radioquimioterapia posterior. Se observó una sobrevida a los 5 años de un 46,4 por ciento, con un control local del tumor de un 70,1 por ciento de los pacientes. Las complicaciones de esta terapia observadas en este grupo de pacientes fueron la cistitis actínica y la rectitis en un porcentaje no superior al 5 por ciento. Por lo tanto se puede plantear a la radioquimioterapia como una alternativa frente a la terapia de pacientes con cáncer vesical avanzado
Subject(s)
Humans , Male , Adult , Female , Middle Aged , Urinary Bladder Neoplasms , Disease-Free Survival , Neoplasm InvasivenessABSTRACT
The antiemetic effect of tropisetron was studied in 97 cancer patients (67 men, 30 women) receiving cisplatin in doses of 75 mg/m² or higher. On 279 chemotherapy cycles studied (max 6 per patient) 5 mg of tropisetron was admonistered once a day i.v. on day 1 and p.o. on day 2 to 6. Efficacy preventing vomiting and nausea was measured in 24 hour period as: complete control 0 episodes, major control 1 to 2 episodes, minor control 3 to 4 episodes and no control 5 or more episodes. Satisfactory vomiting control (complete and major) was 69 percent, 63 percent, 82 percent,88 percent, 96 percent and 96 percent in days 1 to 6 of cycle 1. Satisfactory nausea control (complete and major) for the same day was 70, 66, 72, 85 92 and 97 percent. Similar data was obtained for the subsequeny cycles. Complete vomiting control was obtained in 47, 35, 56, 72, 81 and 84 percent and for nausea in 42, 39, 48, 64, 81 and 87 percent. 19 patients presented adverse effects (19,6 percent). Only 2 headache episodes had a definitive relation with antiemetic drug. 12 patients discontinued the medication; 6 due to drug inefficacy, 2 to illness unrelated to the drug, 1 to lack of collaboration, and 3 due to other reasons. We conclude that tropisetron allows satisfactory control of acute and delayed vomiting in a high percentage of patients treated with high doses of cisplatin. The drug does not have significant secondary effects. Tropisetron administration in only 1 daily dose implies an evident advantage and a treatment cost reduction